Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2017

View Archived Issues

Complex early-onset dystonia is associated with monoallelic variants in KMT2B

Development of BAY-1238097 terminated based on results from first-in-human phase I study

Results from first-in-human multicenter study of bb-2121 in MM

In vitro and in vivo evaluation of [18F]JNJ-64413739 PET tracer

OPKO's phase III study of hGH-CTP does not meet primary endpoint

CTI BioPharma initiates dose-escalation study of pixantrone monotherapy in pediatric patients

Phase II trial of durvalumab with or without tremelimumab in castration-resistant prostate cancer

NantBioScience initiates phase I QUILT-3.013 study of ETBX-021

GlaxoSmithKline initiates phase II study of GSK-2269557 in patients with APDS/PASLI

Phase III trial to compare delafloxacin to moxifloxacin in community-acquired bacterial pneumonia

Incyte begins pivotal REACH-1 trial of ruxolitinib for GvHD

Syros Pharmaceuticals patents c-Myc inhibitors

Vettore discloses MCT4 inhibitors

Sanofi and Boehringer Ingelheim complete business exchange

Bayer Pharma describes mIDH1 inhibitors

FORUM Pharmaceuticals develops nicotinic alpha7 receptor agonists or partial agonists

Sanofi and Merck & Co. end vaccines joint venture in Europe

BGB-A317 begins phase I evaluation in mainland China

Fuji Yakuhin opens phase III study of FYU-981 in patients with hyperuricemia with or without gout

Novartis presents PTP2C inhibitors

Aevi Genomic Medicine initiates phase I study of NFC-1 in subjects aged 6-17 years with ADHD

GlaxoSmithKline and Astex Therapeutics report NRF2 regulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...